Inclusion Criteria:

          1. Capable of giving signed informed consent.

          2. Male or female participants ≥ 18 years of age at the time of screening.

          3. Negative serum pregnancy test at screening and negative serum or urine pregnancy test
             every 3 months during the treatment period (women of childbearing potential only).

          4. Pathologically confirmed tumor that is metastatic, advanced, or recurrent with
             progression for which no alternative or curative therapy exists. Tumors must be TMB-H
             or Strata Immune Signature positive.

          5. Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid
             Tumors (RECIST) 1.1. The measurable lesion must be outside of a radiation field if the
             participant received prior radiation.

          6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

          7. Prior chemotherapy or certain immune therapies or biologic agents must have been
             completed at least 4 weeks (28 days) before investigational product administration and
             all AEs have either returned to baseline or stabilized.

          8. Previously treated brain or meningeal metastases with no evidence of progression by
             magnetic resonance imaging (MRI) for at least 4 weeks (28 days) prior to the first
             dose.

          9. Immunosuppressive doses of systemic medications, such as corticosteroids or absorbed
             topical corticosteroids (doses > 10 mg/day prednisone or equivalent) must be
             discontinued at least 2 weeks (14 days) before investigational product administration.
             Physiologic doses of corticosteroids < 10 mg/day of prednisone or its equivalent may
             be permitted

         10. Prior surgery that required general anesthesia or other major surgery as defined by
             the Investigator must be completed at least 4 weeks before investigational product
             administration

         11. Negative tests for hepatitis B surface antigen, hepatitis C virus antibody (or
             hepatitis C qualitative ribonucleic acid [RNA; qualitative]), and human
             immunodeficiency virus (HIV)-1 and HIV-2 antibody at screening

         12. Adequate organ and marrow function

        Exclusion Criteria:

          1. Use of any live attenuated vaccines against infectious diseases within 4 weeks (28
             days) of initiation of investigational product.

          2. Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will
             make the administration of investigational product hazardous or obscure the
             interpretation of toxicity determination or AEs.

          3. History of myocardial infarction within 6 months or history of arterial thromboembolic
             event within 3 months of the first dose of investigational agent.

          4. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

          5. Is pregnant or breastfeeding or expecting to conceive or father children within the
             projected duration of the study, starting with the pre-screening or screening visit
             through 90 days after the last dose of investigational product.

          6. Any active or documented history of autoimmune disease or history of a syndrome that
             required systemic steroids or immunosuppressive medications.

          7. Any acute gastrointestinal symptoms at the time of screening or admission.

          8. Prior malignancy active within the previous year except for locally curable cancers
             that have been apparently cured.

          9. Prior treatment with an anti-PD-L1, anti-PD-1, anti-CTLA-4, or other immune checkpoint
             inhibitor or agonist as monotherapy or in combination.

         10. Prior treatment with temozolomide.

         11. Use of other investigational drugs (drugs not marketed for any indication) within 28
             days or at least 5 half-lives (whichever is longer) before investigational product
             administration.